Table 3.
Statistical comparison of serum alosetron pharmacokinetic parameters between groups.
| Sex comparsion(female/male)a | Age comparsion(Elderly/Young)a | |||
|---|---|---|---|---|
| Young subjects | Elderly subjects | Male subjects | Female subjects | |
| Intravenous | ||||
| Cmax (ng ml−1) | 1.07 (0.85, 1.35) | 1.25 (1.01, 1.54) | 1.27 (1.05, 1.53)* | 1.48 (1.21, 1.81)* |
| AUC(0, ∞) (ng ml−1 h) | 1.34 (1.02, 1.77) | 1.45 (1.13, 1.87)* | 1.01 (0.81, 1.26) | 1.09 (0.86, 1.39) |
| t1/2 (h) | 1.09 (0.93, 1.26) | 1.06 (0.92, 1.22) | 1.11 (0.98, 1.26) | 1.08 (0.95, 1.24) |
| CL (ml min−1) | 0.75 (0.57, 0.98) | 0.69 (0.53, 0.89)* | 0.99 (0.79, 1.24) | 0.92 (0.72, 1.16) |
| Vss (l) | 0.76 (0.63, 0.92)* | 0.74 (0.62, 0.88)* | 1.02 (0.88, 1.19) | 0.99 (0.84, 1.16) |
| Oral | ||||
| Cmax (ng ml−1) | 1.56 (1.01, 2.41) | 1.86 (1.24, 2.78)* | 0.93 (0.65, 1.32) | 1.11 (0.76, 1.62) |
| tmax (h) | 0.00 (−0.25, 0.25) | 0.00 (−0.25, 0.00) | −0.13 (−0.25, 0.00) | −0.25 (−0.25, 0.00) |
| AUC(0, ∞) (ng ml−1 h) | 1.49 (0.92, 2.41) | 1.87 (1.20, 2.92)* | 0.96 (0.65, 1.42) | 1.21 (0.79, 1.83) |
| t1/2 (h) | 1.00 (0.83, 1.19) | 1.06 (0.90, 1.24) | 1.09 (0.95, 1.26) | 1.16 (0.99, 1.35) |
| F | 0.98 (0.76, 1.27) | 1.24 (0.96, 1.60) | 1.01 (0.79, 1.31) | 1.28 (0.99, 1.65) |
a
Geometric least-square mean ratio (90% confidence interval), except tmax: median difference (90% confidence interval).
*
Significant difference between subject groups (P < 0.05).